## 1 (Brief report)

### 2 Three doses of the BNT162b2 vaccine confer neutralising antibody capacity against the SARS-CoV-2

### 3 B.1.1.529 (Omicron) variant of concern

- 4
- Kevin K. Ariën<sup>1,2,\*</sup>, Leo Heyndrickx<sup>1</sup>, Johan Michiels<sup>1</sup>, Katleen Vereecken<sup>1</sup>, Kurt Van Lent<sup>3</sup>, Sandra 5
- Coppens<sup>1</sup>, Pieter Pannus<sup>4</sup>, Geert A. Martens<sup>5</sup>, Marjan Van Esbroeck<sup>3</sup>, Maria E. Goossens<sup>4</sup>, Arnaud 6

7 Marchant<sup>6</sup>, Koen Bartholomeeusen<sup>1</sup>, Isabelle Desombere<sup>7</sup>

- 8
- 9 <sup>1</sup>Virology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine Antwerp, Antwerp,
- 10 Belgium
- <sup>2</sup> Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium 11
- 12 <sup>3</sup> Department of Clinical Sciences, Institute of Tropical Medicine Antwerp, Antwerp, Belgium
- <sup>4</sup> SD Epidemiology and Public Health, Sciensano, Brussels, Belgium 13
- <sup>5</sup> Department of Laboratory Medicine, AZ Delta General Hospital, Roeselare, Belgium 14
- <sup>6</sup> Institute for Medical Immunology and ULB Center for Research in Immunology (U-CRI), Université 15
- 16 libre de Bruxelles (ULB), Gosselies, Belgium
- 17 <sup>7</sup> Immune response, SD Infectious Diseases in Humans, Sciensano, Brussels, Belgium
- 18 \*correspondence: karien@itg.be

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

2

## 19 Abstract

We report the levels of neutralising antibodies against Wuhan, Delta and Omicron variants in healthy individuals pre-infected or not with SARS-CoV-2 and immunized with three doses of the BNT162b2 vaccine. Our observations support the rapid administration of a booster vaccine dose to prevent infection and disease caused by Omicron.

24

# 25 Introduction

26 Researchers in Botswana and South Africa identified a new and heavily mutated SARS-CoV-2 variant 27 (B.1.1.529, Omicron) in late November 2021, with 30 amino acid mutations in the Spike protein that 28 are distinct compared to other variants of concern (VOC) Alpha, Beta and Delta [1]. Omicron is 29 characterized by fast spreading in previously vaccinated populations, suggesting Omicron's ability to 30 evade vaccine-induced immunity [2] and therapeutic monoclonal antibody therapy [3]. Several recent pre-print studies have indeed confirmed a substantial reduction in neutralising antibody 31 32 activity against Omicron in small-scaled studies including previously infected individuals, fully 33 vaccinated individuals, recipients of third booster doses of BNT162b2 or mRNA-1273 and individuals 34 with hybrid immunity (infection followed by vaccination) [4-9]. The common trend from these first 35 laboratory-based assessments is that the potency to neutralise Omicron is reduced by approximately 40-fold (20-200-fold depending on the study) compared to the original Wuhan D614G virus. 36

Here, we have assessed the levels of neutralising antibodies (nAb) against the original Wuhan strain,
Delta (B.1.617.2) and Omicron (B.1.1.529) VOC of 30 sera collected from individuals infected with
SARS-CoV-2 prior to vaccination (Group 1), from infection-naïve individuals after three doses of
BNT162b2 (Group 2) and from previously-infected individuals after three doses of BNT162b2 (Group
3).

42

## 43 Methods

44 Omicron variant isolation and sequence confirmation

3

45 An Omicron virus isolate was made from a nasopharyngeal (NP) swab collected from a patient with 46 sequence-confirmed Omicron infection returning from a stay in the Republic of South Africa. An 47 additional NP swab was collected 48h after RT-qPCR diagnosis and 24h after sequence confirmation of infection with the Omicron variant. The patient was infected after a complete course of 48 49 vaccination with mRNA-1273 (Moderna) and presented with mild symptoms (cough, sore throat). 50 The NP swap was collected on universal transport medium (UTM) and transferred fresh to the BSL3 51 laboratory immediately after collection. Two times 200 $\mu$ l of 1/2 diluted sample and 2x 200 $\mu$ l of 1/4 52 diluted sample (in Vero cell medium with 2% FBS) were added to a 80-100% confluent layer of Vero 53 cells plated 1.5h before in 24-well plates in Vero cell medium with 2% FBS (300.000 cells/well, plates 54 were incubated at 37°C and 7% CO2 before inoculation). Cells were spinoculated for 30 min. at 2500 55 g and 37°C, then placed again for 10-15 min. in the incubator, after which 800µl of fresh Vero cell 56 medium with 2% FBS was added. Plates were subsequently incubated at 37° and 7% CO2 and 57 cytopathogenic effect (CPE) was scored daily by microscopy. On day 4 post inoculation, CPE was 58 clearly visible in all inoculated wells and virus supernatant from all 4 wells was collected and pooled. 59 Virus was further passaged a second time on Vero cells by adding 2 ml of the freshly collected virus 60 suspension to 95-100% confluently grown Vero cells in a T175 culture flask and incubated for 2h at 61 37°C and 7% CO2. Next, the cells were washed with PBS, 35ml of fresh Vero cell medium with 2% FBS was added and cells were incubated again at 37° and 7% CO2. On day 4 CPE was clearly visible and 62 63 virus was collected, centrifuged for 5 min. at 3220 g to remove debris, aliquoted and stored at -80°C. 64 Sequence confirmation regarding Omicron classification was obtained by sequencing the Spike gene on passage 1 of the viral isolate. Viral RNA was extracted using the QIAamp viral RNA mini kit 65 (Qiagen) and the Spike coding sequence was RT-PCR amplified with primer sets COV2-800-39R 66 (CAAAGGCACGCTAGTAGTCGTC), COV2-800-32L (GGGTGTTGCTATGCCTAATCTTTACA), COV2-800-38R 67 (TGCAGTAGCGCGAACAAAATCT) and COV2-800-33L (TGCATGCAAATTACATATTTTGGAGGA), and 68 subsequently sequenced with primers COV2-800-34L (GTTGGATGGAAAGTGAGTTCAGAGT), COV2-69 70 800-35L (TTCCGCATCATTTTCCACTTTTAAGT), COV2-800-36L (TGCACAGAAGTCCCTGTTGCTA), COV2-

4

71 800-37L (TGCAGATGCTGGCTTCATCAAA), COV2-800-38L (CTTCCCTCAGTCAGCACCTCAT), COV2-800-72 32L (GGGTGTTGCTATGCCTAATCTTTACA), COV2-800-39R (CAAAGGCACGCTAGTAGTCGTC), COV2-800-73 33L (TGCATGCAAATTACATATTTTGGAGGA), and COV2-800-38R (TGCAGTAGCGCGAACAAAATCT) 74 (adapted from [10]). Using BLAST+, the obtained Spike sequence was found to be identical to a 75 recently published SARS-CoV-2 Omicron sequence from Belgium (GenBank accession number 76 UFO69279.1).

- 77
- 78 SARS-CoV-2 whole-virus neutralisation assay

79 SARS-CoV-2 neutralising antibodies were quantified as previously reported [11,12]. Briefly, serial dilutions of heat-inactivated serum (1/50-1/25600 in EMEM supplemented with 2 mM L-glutamine, 80 81 100 U/ml-100 µg/ml of Penicillin–Streptomycin and 2% fetal bovine serum) were incubated during 1 82 h (37 °C, 7% CO2) with 3xTCID100 of wild type (WT) Wuhan strain (2019-nCoV-Italy-INMI1, reference 008 V-03893), 83DJ-1 (B.1.617.2, Delta) or VLD20211207 (B.1.1.529, Omicron). One hundred µl of 83 84 sample-virus mixtures and virus/cell controls were added to 100µl of Vero cells (18.000 cells/well) in 85 a 96-well plate and incubated for five days (37 °C, 7% CO2). The CPE caused by viral growth was 86 scored microscopically. The Reed–Muench method was used to calculate the nAb titer that reduced the number of infected wells by 50% (NT50), which was used as a proxy for the nAb concentration in 87 88 the sample. The Mann-Whitney test was used to compare Wuhan and variant nAb titers.

89

# 90 Results and discussion

91 We tested three representative patient groups for neutralising antibody capacity against Wuhan, 92 Delta and Omicron variants of SARS-CoV-2 in a whole-virus neutralisation assay (Figure 1). Group 1 93 sera (n=10) were obtained from COVID-19 patients hospitalized with severe infection. All patients 94 were infected between 24 Feb 2020 and 27 March 2020 when Wuhan D614G was the only variant 95 circulating and when vaccines were not yet available. Samples tested were collected with a median 96 time after onset of symptoms of 25 days [range 13-46]. Group 2 sera (n=10) were obtained from

5

97 individuals without a documented previous SARS-CoV-2 infection and 28 days after third dose of
98 BNT162b2. All individuals were vaccinated with a 21-day interval between dose 1 and 2 and received
99 third dose 7 months (median 211 days [207-219]) after dose 2. Group 3 sera (n=10) were obtained
100 from individuals with hybrid immunity, i.e. individuals who have had a previous infection with Wuhan
101 D614G between 24 March 2020 and 11 June 2020, followed by three doses of the BNT162b2 vaccine.
102 Dose 1 and dose 2 were given 21-days apart and the third dose was administered with a median time
103 interval of 8 months (median 261 days [218-290]) after dose 2.

104

105 Individuals with immunity after infection but without vaccination (Group 1) have the lowest nAb 106 responses regardless of the variant tested (Geometric mean titer (GMT)<sub>Wuhan</sub> 1086, GMT<sub>Delta</sub> 151, 107 GMT<sub>Omicron</sub> <50) (Figure 1). Infection-naïve individuals that received three doses of the BNT162b2 108 vaccine (Group 2) showed significantly higher nAb levels against Wuhan (GMT<sub>Wuhan</sub> 2157), Delta 109 (GMT<sub>Delta</sub> 477) and Omicron (GMT<sub>Omicron</sub> 165). Individuals with hybrid immunity (Group 3) showed the 110 highest NT50 values against Wuhan (GMT<sub>Wuhan</sub> 4822), Delta (GMT<sub>Delta</sub> 1159) and Omicron (GMT<sub>Omicron</sub> 111 236) variants, but the nAb levels for Omicron were not statistically different between Groups 2 and 3. 112 We observed a significant reduction in NT50 across the three groups for the Delta variant (Group 1: 113 7.2 fold reduction; Group 2: 4.5 fold reduction; Group 3: 4.2 fold reduction in GMT) and a 114 significantly larger reduction against the Omicron variant (Group 1: >22 fold reduction; Group 2: 13.1 115 fold reduction; Group 3: 20.5 fold reduction in GMT). This drop in nAb titer is most pronounced for 116 Group 1 (infection/no vaccination), but even for triple vaccinated subjects with (Group 3) or without (Group 2) previous infection, the  $NT50_{Omicron}$  is significantly lower than for the Wuhan and Delta 117 118 strains. Our data confirm the earlier observation that three doses of the mRNA vaccine BNT162b2 119 results in high neutralising antibody titers for the three variants tested. Although hybrid immunity 120 obtained through infection and subsequent vaccination results in significantly higher nAb levels 121 against Wuhan and Delta, the difference for Omicron is not statistically significant compared to the 122 3-dose BNT162b2 vaccine schedule.

6

123	In this study, we analysed only one critical component of immunity to SARS-CoV-2. Non-neutralizing
124	functions of antibodies and T-cell responses may be less affected by mutations of the Omicron
125	variant and may thereby provide some compensation to immune escape. While multiple studies,
126	including ours, have provided evidence that the Omicron variant can escape naturally acquired and
127	vaccine-induced immune responses, disease severity caused by the variant remains unclear.
128	
129	In conclusion, our findings confirm that three doses of the BNT162b2 vaccine confers neutralising
130	antibody capacity against Omicron, and that vaccine-induced responses (Groups 2 and 3) outperform
131	naturally-acquired immunity (Group 1). Hybrid immunity (Group 3) results in significantly higher nAb
132	levels against Wuhan and Delta, but not against Omicron. The observation that a 2-dose schedule of
133	BNT162b2 is not sufficient to neutralize Omicron [6,7,9] warrants for rapid administration of a

134 booster vaccine dose to counter infection and limit disease caused by this variant.

7

Author contributions. KKA wrote the paper. LH, JM, KV, KVL, SC, PP, MVE and KB conducted 135 experimental work and data analysis. KKA, AM, ID conceived the study. KKA and MEG were 136 responsible to obtain the funding. All authors read, edited and approved the final manuscript. 137 138 139 Acknowledgements. We are grateful to Guido Vanham for critically reviewing the manuscript, to 140 Caroline Rodeghiero and Sarah Houben for logistical and administrative support. 141 142 Financial support. This work was supported by the Belgian Federal Government through Sciensano 143 (COVID-19\_SC004, \_SC049, \_SC059, \_SC103) and the Research Foundation Flanders (FWO G0G4220N). 144 145 146 Potential conflicts of interest. All authors: No reported conflicts of interest. 147 148 References 149 1. Viana R, Moyo S, Amoako DG, et al. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. medRxiv 2021.12.19.21268028 150 2. Pulliam JRC, van Schalkwyk C, Govender N, et al. Increased risk of SARS-CoV-2 reinfection 151 associated with emergence of the Omicron variant in South Africa. medRxiv 152 153 2021.11.11.21266068 154 3. Aggarwal A, Stella AO, Walker G, et al. SARS-CoV-2 Omicron: evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern. 155 medRxiv 2021.12.14.21267772 156 157 4. Cele S, Jackson L, Khan K, et al. SARS-CoV-2 Omicron has extensive but incomplete escape of 158 Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection. medRxiv 2021.12.08.21267417 159

8

160	5.	Rössler A, Riepler L, Bante D, von Laer D, Kimpel J. SARS-CoV-2 B.1.1.529 variant (Omicron)
161		evades neutralization by sera from vaccinated and convalescent individuals.
162		medRxiv 2021.12.08.21267491
163	6.	Hansen CH, Schelde AB, Moustsen-Helms IR, et al. Vaccine effectiveness against SARS-CoV-2
164		infection with the Omicron or Delta variants following a two-dose or booster BNT162b2 or
165		mRNA-1273 vaccination series: A Danish cohort study. medRxiv 2021.12.20.21267966
166	7.	Nemet I, Kliker L, Lustig Y, et al. Third BNT162b2 vaccination neutralization of SARS-CoV-2
167		Omicron infection. medRxiv 2021.12.13.21267670
168	8.	Schmidt F, Muecksch F, Weisblum Y, et al. Plasma neutralization properties of the SARS-CoV-
169		2 Omicron variant. medRxiv 2021.12.12.21267646
170	9.	Lustig Y, Gonen T, Meltzer L, et al. Superior immunogenicity and effectiveness of the 3rd
171		BNT162b2 vaccine dose. medRxiv 2021.12.19.21268037
172	10.	Selhorst P, van Ierssel SH, Michiels J, et al. Symptomatic Severe Acute Respiratory Syndrome
173		Coronavirus 2 Reinfection of a Healthcare Worker in a Belgian Nosocomial Outbreak Despite
174		Primary Neutralizing Antibody Response. Clin Infect Dis. 2021 Nov 2;73(9):e2985-e2991.
175	11.	Mariën J, Ceulemans A, Michiels J, et al. Evaluating SARS-CoV-2 spike and nucleocapsid
176		proteins as targets for antibody detection in severe and mild COVID-19 cases using a Luminex
177		bead-based assay. J Virol Methods. 2021 Feb;288:114025
178	12.	Pannus P, Neven KY, De Craeye S, et al. Poor antibody response to BioNTech/Pfizer COVID-19

179 vaccination in SARS-CoV-2 naïve residents of nursing homes. Clin Infect Dis. 2021 Dec

180 3:ciab998

9



182

183 Figure 1: (A) Patient sera characteristics. (B) Neutralising antibody titers (NT50) against Wuhan, Delta and Omicron viruses. GMT (Geometric mean titer), P values Mann-Whitney test: \*\*\* (<0.001), \*\* 184 (<0.01). The dotted line represents the assay cut-off ( $NT_{50}$ =50). 185